Gsk (GLAXF) Debt to Equity (2016 - 2025)
Gsk has reported Debt to Equity over the past 10 years, most recently at $1.08 for Q4 2025.
- Quarterly results put Debt to Equity at $1.08 for Q4 2025, down 12.77% from a year ago — trailing twelve months through Dec 2025 was $1.08 (down 12.77% YoY), and the annual figure for FY2025 was $1.08, down 12.77%.
- Debt to Equity for Q4 2025 was $1.08 at Gsk, down from $1.24 in the prior quarter.
- Over the last five years, Debt to Equity for GLAXF hit a ceiling of $1.73 in Q4 2022 and a floor of $1.08 in Q4 2025.
- Median Debt to Equity over the past 5 years was $1.35 (2023), compared with a mean of $1.37.
- Biggest five-year swings in Debt to Equity: grew 20.74% in 2022 and later fell 21.98% in 2023.
- Gsk's Debt to Equity stood at $1.43 in 2021, then rose by 20.74% to $1.73 in 2022, then dropped by 21.98% to $1.35 in 2023, then decreased by 8.1% to $1.24 in 2024, then dropped by 12.77% to $1.08 in 2025.
- The last three reported values for Debt to Equity were $1.08 (Q4 2025), $1.24 (Q4 2024), and $1.35 (Q4 2023) per Business Quant data.